Targeting fibroblast derived thrombospondin 2 disrupts an immune-exclusionary environment at the tumor front in colorectal cancer
Year: 2025
Type: article
Abstract: Fibrotic colorectal cancers (CRC) are largely microsatellite-stable and display desmoplastic stroma with poor immune infiltration. Here we identify thrombospondin-2 (THBS2) as a key regulator of the immune-exclusionary phenotype in fibrotic CRC. THBS2 is highly expressed by matrix cancer-associated fibroblasts at the tumor front. In an orthotopic model using desmoplastic tumor organoids, global or fibroblast-specific Thbs2 deletion disrupts the exclusionary barrier and increases intratumoral CD8 T cells. Mechanistically, THBS2 limits recruitment of CXCR3+ CD8 T cells by restraining dendritic- and macrophage-derived CXCL9/10. Depletion of these myeloid cells or blockade of CXCL9/10-CXCR3 signaling abolishes the enhanced CD8 T-cell influx and antitumor efficacy. Spatial profiling demonstrates that THBS2 loss induces proximity between CD8 T cells and myeloid cells and upregulates chemokines. Despite increased infiltration, CD8 T cells manifest exhaustion, rendering tumors highly susceptible to immune checkpoint blockade. THBS2 thus represents a tractable CAF-restricted target to overcome immune exclusion in fibrotic CRCs. Desmoplastic stroma is a hallmark of aggressive colorectal cancer. Matrix cancer-associated fibroblasts derived THBS2 establishes a fibrotic, immune-exclusionary barrier that limits CD8+ T cell infiltration, while its inhibition restores CXCR3-mediated T cell recruitment and enhances response to immune checkpoint blockade.
Source: Nature Communications
Authors: Kosuke Iwane(Writing – review & editing), Yuki Nakanishi(Conceptualization, Methodology, Supervision, Writing – original draft, Writing – review & editing), Yu Muta(Writing – review & editing), Jiayu Chen(Investigation, Writing – review & editing), Kento Yasumura(Investigation, Writing – review & editing), Mayuki Omatsu(Investigation, Writing – review & editing), Naoki Aoyama(Writing – review & editing), Munehiro Ikeda(Investigation, Writing – review & editing), Yoko Masui(Writing – review & editing), Liyang Cai(Investigation, Writing – review & editing), Go Yamakawa(Investigation, Writing – review & editing), Kensuke Hamada(Investigation, Writing – review & editing), Kenta Mizukoshi(Writing – review & editing), Munenori Kawai(Investigation, Writing – review & editing), Kei Iimori(Writing – review & editing), Shinnosuke Nakayama(Investigation, Writing – review & editing), Nobukazu Agatsuma(Writing – review & editing), Takahiro Utsumi(Investigation, Writing – review & editing), Munemasa Nagao(Writing – review & editing), Takahisa Maruno(Investigation, Writing – review & editing), Yukiko Hiramatsu(Investigation, Writing – review & editing), Nobuyuki Kakiuchi(Investigation, Writing – review & editing), Masahiro M. Nakagawa(Investigation, Writing – review & editing), Yasuhiro Fukui(Writing – review & editing), Yukina Kusunoki(Investigation, Writing – review & editing), Hiroaki Kasashima(Investigation, Writing – review & editing), Masakazu Fujimoto(Investigation, Writing – review & editing), Yoshiro Itatani(Resources, Writing – review & editing), Toshiaki Kogame(Resources, Writing – review & editing), Akihisa Fukuda(Investigation, Writing – review & editing), Masakazu Yashiro(Resources, Writing – review & editing), Kiyoshi Maeda(Writing – review & editing), Kenji Kabashima(Resources, Writing – review & editing), Kazutaka Obama(Resources, Writing – review & editing), Seishi Ogawa(Investigation, Writing – review & editing), Maria T. Diaz-Meco(Resources, Writing – review & editing), Jorge Moscat(Resources, Writing – review & editing), Hiroshi Seno(Supervision, Writing – review & editing)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $6,990
Funders: Japan Agency for Medical Research and Development, Ministry of Education, Culture, Sports, Science and Technology, Cabinet Office, Government of Japan, Astellas Pharma, Japan Society for the Promotion of Science, Co-creation place formation support program, Moonshot Research and Development Program, Fusion Oriented REsearch for disruptive Science and Technology, Daiichi Sankyo Europe
Awards: G1500074213, G1829471703, G2639341719, G2739244484, Development of hybrid strategies to overcome therapeutic resistance in colorectal cancer, 肝外胆道がん、胆嚢がんの自然史に沿った網羅的解析と治療標的の検討, RECKをエフェクターとした新規膵癌治療法の開発, G5255304557, G5343035205, G5447148599, G5563469725, 大腸がん幹細胞の可塑性を制御する時空間的メカニズムの解析, ヒト膵癌の転移、進行におけるRECKの機能的役割の解明, G6522694557, 高悪性度消化器がんの免疫微小環境における「内部と外部」制御因子の解明, G6811804392, G764922153, G7774910322, 胆道がんの多様性を考慮した早期検出法の開発, G8906743551
OpenAlex ID: W4416624997
